{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T14:33:00Z","timestamp":1777905180434,"version":"3.51.4"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,9]],"date-time":"2025-07-09T00:00:00Z","timestamp":1752019200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100020097","name":"Foundation for Opioid Response Efforts","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020097","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug and Alcohol Dependence Reports"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.dadr.2025.100360","type":"journal-article","created":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T23:07:17Z","timestamp":1752620837000},"page":"100360","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Addressing wholesale distributor barriers to buprenorphine access: Consensus recommendations from the PhARM-OUD expert panel"],"prefix":"10.1016","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9795-8837","authenticated-orcid":false,"given":"Tyler J.","family":"Varisco","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6017-7500","authenticated-orcid":false,"given":"Douglas","family":"Thornton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-3723-7869","authenticated-orcid":false,"given":"Taha","family":"Hussain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1200-3714","authenticated-orcid":false,"given":"Hannah","family":"Fish","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joshua","family":"Bolin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9247-3168","authenticated-orcid":false,"given":"David","family":"Dadiomov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8157-8290","authenticated-orcid":false,"given":"Ekere J.","family":"Essien","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew A.","family":"Wanat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diane","family":"Ginsburg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeanne","family":"Waggener","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2240-5768","authenticated-orcid":false,"given":"Jeffrey P.","family":"Bratberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bethany","family":"DiPaula","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5958-0159","authenticated-orcid":false,"given":"Lucas G.","family":"Hill","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.dadr.2025.100360_bib1","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/1471-2288-5-37","article-title":"Stability of response characteristics of a Delphi panel: application of bootstrap data expansion","volume":"5","author":"Akins","year":"2005","journal-title":"BMC Med. Res. Method."},{"key":"10.1016\/j.dadr.2025.100360_bib2","unstructured":"American Society of Addiction Medicine, 2024. Report Pharmacy Access Issues [WWW Document]. URL \u3008https:\/\/www.surveymonkey.com\/r\/ASAMpharmacy\u3009 (accessed 12.5.24)."},{"key":"10.1016\/j.dadr.2025.100360_bib3","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1080\/2159676X.2019.1628806","article-title":"Reflecting on reflexive thematic analysis","volume":"11","author":"Braun","year":"2019","journal-title":"Qual. Res. Sport Exerc. Health"},{"key":"10.1016\/j.dadr.2025.100360_bib4","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1016\/j.japh.2022.04.019","article-title":"North Carolina community pharmacists\u2019 buprenorphine dispensing practices and attitudes","volume":"62","author":"Carpenter","year":"2022","journal-title":"J. Am. Pharm. Assoc. JAPhA"},{"key":"10.1016\/j.dadr.2025.100360_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugpo.2020.102701","article-title":"Buprenorphine dispensing in an epicenter of the U.S. opioid epidemic: a case study of the rural risk environment in Appalachian Kentucky","volume":"85","author":"Cooper","year":"2020","journal-title":"Int. J. Drug Policy"},{"key":"10.1016\/j.dadr.2025.100360_bib6","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1056\/NEJMp2002908","article-title":"When prescribing isn\u2019t enough - pharmacy-level barriers to buprenorphine access","volume":"383","author":"Cooper","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.dadr.2025.100360_bib7","doi-asserted-by":"crossref","first-page":"c5475","DOI":"10.1136\/bmj.c5475","article-title":"Risk of death during and after opiate substitution treatment in primary care: prospective observational study in UK General Practice Research Database","volume":"341","author":"Cornish","year":"2010","journal-title":"BMJ"},{"key":"10.1016\/j.dadr.2025.100360_bib8","unstructured":"Department of Justice, 2022. FINAL AGREEMENT 3.25.22. EXHIBIT C AS OF 5.27.22; EXHIBIT G AS OF 01.10.23. Exhibit P. Injunctive Relief."},{"key":"10.1016\/j.dadr.2025.100360_bib9","doi-asserted-by":"crossref","DOI":"10.15585\/mmwr.mm7325a1","article-title":"Treatment for opioid use disorder: population estimates \u2014 United States, 2022","volume":"73","author":"Dowell","year":"2024","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"10.1016\/j.dadr.2025.100360_bib10","doi-asserted-by":"crossref","DOI":"10.1001\/jamahealthforum.2024.1077","article-title":"Barriers to buprenorphine dispensing by medicaid-participating community retail pharmacies","volume":"5","author":"Freeman","year":"2024","journal-title":"JAMA Health Forum"},{"key":"10.1016\/j.dadr.2025.100360_bib11","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/add.15998","article-title":"The association between buprenorphine treatment duration and mortality: a multi-site cohort study of people who discontinued treatment","volume":"118","author":"Glanz","year":"2023","journal-title":"Addict. Abingdon Engl."},{"key":"10.1016\/j.dadr.2025.100360_bib12","series-title":"Sociological Methods","article-title":"Theoretical sampling","author":"Glaser","year":"2006"},{"key":"10.1016\/j.dadr.2025.100360_bib13","unstructured":"Health and Human Services, 2023. Telehealth policy changes after the COVID-19 public health emergency | Telehealth.HHS.gov [WWW Document]. URL https:\/\/telehealth.hhs.gov\/providers\/telehealth-policy\/policy-changes-after-the-covid-19-public-health-emergency (accessed 11.15.24)."},{"key":"10.1016\/j.dadr.2025.100360_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2022.109518","article-title":"Availability of buprenorphine\/naloxone films and naloxone nasal spray in community pharmacies in 11 U.S. states","volume":"237","author":"Hill","year":"2022","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.dadr.2025.100360_bib15","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.japh.2024.01.013","article-title":"Addressing buprenorphine supply barriers: a guidance commentary","volume":"64","author":"Khail","year":"2024","journal-title":"J. Am. Pharm. Assoc."},{"key":"10.1016\/j.dadr.2025.100360_bib16","doi-asserted-by":"crossref","first-page":"137","DOI":"10.7326\/M17-3107","article-title":"Medication for opioid use disorder after nonfatal opioid overdose and association with mortality: a cohort Study","volume":"169","author":"Larochelle","year":"2018","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.dadr.2025.100360_bib17","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.im.2003.11.002","article-title":"The Delphi method as a research tool: an example, design considerations and applications","volume":"42","author":"Okoli","year":"2004","journal-title":"Inf. Manag."},{"key":"10.1016\/j.dadr.2025.100360_bib18","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1097\/ADM.0000000000000762","article-title":"DEA Disconnect Leads to Buprenorphine Bottlenecks","volume":"15","author":"Ostrach","year":"2021","journal-title":"J. Addict. Med."},{"key":"10.1016\/j.dadr.2025.100360_bib19","doi-asserted-by":"crossref","DOI":"10.1001\/jamahealthforum.2022.2839","article-title":"Federal and state pharmacy regulations and dispensing barriers to buprenorphine access at retail pharmacies in the US","volume":"3","author":"Qato","year":"2022","journal-title":"JAMA Health Forum"},{"key":"10.1016\/j.dadr.2025.100360_bib20","unstructured":"Rep. Walden, G. [R-O.-2, 2018. H.R.6 - 115th Congress (2017-2018): An act to provide for opioid use disorder prevention, recovery, and treatment, and for other purposes [WWW Document]. URL \u3008https:\/\/www.congress.gov\/bill\/115th-congress\/house-bill\/6\u3009 (accessed 8.29.24)."},{"key":"10.1016\/j.dadr.2025.100360_bib21","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1001\/jamapsychiatry.2021.0976","article-title":"Association of opioid agonist treatment with all-cause mortality and specific causes of death among people with opioid dependence: a systematic review and meta-analysis","volume":"78","author":"Santo","year":"2021","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.dadr.2025.100360_bib22","unstructured":"Sen. Hassan, M.W. [D-N., 2021. S.445 - 117th Congress (2021-2022): Mainstreaming Addiction Treatment Act of 2021 [WWW Document]. URL \u3008https:\/\/www.congress.gov\/bill\/117th-congress\/senate-bill\/445\u3009 (accessed 3.24.24)."},{"key":"10.1016\/j.dadr.2025.100360_bib23","unstructured":"Sen. Heinrich, M. [D-N., 2024. Text - S.5271 - 118th Congress (2023-2024): BUPE for Recovery Act [WWW Document]. URL \u3008https:\/\/www.congress.gov\/bill\/118th-congress\/senate-bill\/5271\/text\/is\u3009 (accessed 10.25.24)."},{"key":"10.1016\/j.dadr.2025.100360_bib24","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.51856","article-title":"Trends and characteristics of buprenorphine-involved overdose deaths prior to and during the COVID-19 pandemic","volume":"6","author":"Tanz","year":"2023","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.dadr.2025.100360_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugpo.2022.103703","article-title":"Red Flags\u201d and \u201cRed Tape\u201d: telehealth and pharmacy-level barriers to buprenorphine in the United States","volume":"105","author":"Textor","year":"2022","journal-title":"Int. J. Drug Policy"},{"key":"10.1016\/j.dadr.2025.100360_bib26","unstructured":"United States House Committee on Oversight and Accountability, 2024. Hearing Wrap Up: Oversight Committee Exposes How PBMs Undermine Patient Health and Increase Drug Costs [WWW Document]. U. S. House Comm. Overs. Account. URL \u3008https:\/\/oversight.house.gov\/release\/hearing-wrap-up-oversight-committee-exposes-how-pbms-undermine-patient-health-and-increase-drug-costs\/\u3009 (accessed 12.5.24)."},{"key":"10.1016\/j.dadr.2025.100360_bib27","series-title":"The pharmacy access to resources and medication for opioid use disorder (PhARM-OUD) guideline","author":"Varisco","year":"2024"},{"key":"10.1016\/j.dadr.2025.100360_bib28","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s13690-024-01287-4","article-title":"Protocol for the development of a consensus practice guideline To address clinical and regulatory barriers to buprenorphine dispensing in community pharmacy","volume":"82","author":"Varisco","year":"2024","journal-title":"Arch. Public Health"},{"key":"10.1016\/j.dadr.2025.100360_bib29","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1016\/j.japh.2023.04.016","article-title":"The impact of the mainstreaming addiction treatment act and associated legislative action on pharmacy practice","volume":"63","author":"Varisco","year":"2023","journal-title":"J. Am. Pharm. Assoc. JAPhA"},{"key":"10.1016\/j.dadr.2025.100360_bib30","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1080\/10826084.2019.1670210","article-title":"Communication experiences of DATA-waivered physicians with community pharmacists: a qualitative study","volume":"55","author":"Ventricelli","year":"2020","journal-title":"Subst. Use Misuse"},{"key":"10.1016\/j.dadr.2025.100360_bib31","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.16089","article-title":"Pharmacy availability of buprenorphine for opioid use disorder treatment in the US","volume":"6","author":"Weiner","year":"2023","journal-title":"JAMA Netw. Open"}],"container-title":["Drug and Alcohol Dependence Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772724625000435?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772724625000435?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T12:40:08Z","timestamp":1777639208000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2772724625000435"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":31,"alternative-id":["S2772724625000435"],"URL":"https:\/\/doi.org\/10.1016\/j.dadr.2025.100360","relation":{},"ISSN":["2772-7246"],"issn-type":[{"value":"2772-7246","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Addressing wholesale distributor barriers to buprenorphine access: Consensus recommendations from the PhARM-OUD expert panel","name":"articletitle","label":"Article Title"},{"value":"Drug and Alcohol Dependence Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dadr.2025.100360","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"100360"}}